The "better safety in drug supply" draft law (GSAV) plans to strengthen the monitoring and control procedures of drugs on the German market and modify the HTA procedure for medicinal products that have been granted an accelerated or simplified authorisation. Experts from the Ministry of Health and umbrella payer group GKV-Spitzenverband will review the changes to be anticipated.
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.